Exelixis EXEL Cotellic — Revenue
Discontinued — last reported Q4 '24
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-K, filed February 11, 2025, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's cotellic — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's cotellic — revenue?
- Exelixis (EXEL) reported cotellic — revenue of $3.4M in Q4 2024.
- How has Exelixis's cotellic — revenue changed year-over-year?
- Exelixis's cotellic — revenue decreased by 19.5% year-over-year, from $4.23M to $3.4M.
- What is the long-term trend for Exelixis's cotellic — revenue?
- Over 3 years (2021 to 2024), Exelixis's cotellic — revenue has grown at a 4.0% compound annual growth rate (CAGR), from $12.1M to $13.6M.
- What does cotellic — revenue mean?
- The total sales revenue generated by the Cotellic pharmaceutical product.
- How do you interpret cotellic — revenue?
- An increase indicates growing market adoption or successful expansion of the product's clinical indications, while a decrease may signal increased competition or product maturity.
- How does cotellic — revenue compare across companies?
- Comparable to product-specific net sales reported by other biopharmaceutical companies for individual oncology assets.